Idera pharmaceuticals, inc. (IDRA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash Flows from Operating Activities:
Net income (loss)

-56,515

-59,881

-65,984

-38,389

-48,555

-

-

-

-

-

-

Net loss

-

-

-

-

-

-38,642

-

-

-

-

-

Net loss

-

-

-

-

-

-

-18,226

-19,240

-23,776

-17,963

7,546

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Loss from disposition of assets

-

-

-

-

-

-

-

-4

-1

-

-

Non-employee stock option expense

-

-

-

-

143

24

121

-

-

-

-

Stock-based compensation

3,845

5,674

10,720

6,847

5,442

4,322

1,398

2,096

2,725

3,684

3,093

Warrant liability revaluation income

598

-

-

-

-

-

-

-

-

-

-

Future tranche right liability revaluation income

10,964

-

-

-

-

-

-

-

-

-

-

Loss from disposition of assets

-

-

-

-

-

-

-

-

-

-2

-

Issuance of common stock for services rendered

129

97

150

172

122

82

26

5

1

14

9

Cost of regaining rights to cancer program

-

-

-

-

-

-

-

-

2,423

-

-

Decrease in fair value of warrant liability

-

-

-

-

-

-

-

675

1,974

-

-

Issuance of common stock for services rendered

-

-

-

-

-

-

-

1

38

8

17

Accretion of discounts on short-term investments

372

-

-94

-566

-599

-213

-9

-

-62

-253

-40

Depreciation and amortization expense

120

432

746

656

488

206

137

251

494

-

-

Gain on disposal of property and equipment

10

-477

-

-4

-

-1

-

-

-

-

-

Depreciation expense

-

-

-

-

-

-

-

-

-

546

563

Changes in operating assets and liabilities:
Accounts receivable

-

-

-

-

-

-

-

-

-

-4,495

4,023

Prepaid expenses and other assets

2,160

-2,717

1,962

-1,064

1,889

329

676

-57

-640

-139

154

Accounts payable, accrued expenses, and other liabilities

-1,105

-866

1,674

1,988

-1,709

2,802

-

-

-

-

-

Accounts payable, accrued expenses, and other liabilities

-

-

-

-

-

-

74

-2,415

174

1,431

-383

Deferred revenue

-

-566

-697

-1,111

2,373

-

-

-

-

-

-

Other

-8

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-12,165

-22,295

Net cash used in operating activities

-44,498

-51,916

-55,259

-28,203

-42,986

-

-

-

-19,192

-19,556

-15,587

Net cash used in operating activities

-

-

-

-

-

-31,321

-17,137

-19,916

-

-

-

Cash Flows from Investing Activities:
Purchases of available-for-sale securities

44,502

-

-

2,946

63,106

23,623

9,331

-

1,025

10,319

14,768

Proceeds from maturity of available-for-sale securities

42,100

-

28,270

32,746

29,420

4,115

-

-

18,585

7,200

10,450

Proceeds from sale of available-for-sale securities

-

-

-

1,974

-

-

-

-

-

-

-

Proceeds from the sale of property and equipment

11

290

-

-

-

-

-

-

-

-

-

Proceeds from sale of available-for-sale securities

-

-

-

-

999

-

-

-

-

-

-

Decrease in restricted cash

-

-

-

-

-

-

-

-

-102

-103

-102

Purchases of property and equipment

11

75

206

408

727

1,093

9

-

23

92

126

Net cash used in investing activities

-2,402

215

28,064

31,366

-33,414

-

-

-

17,639

-3,108

-4,342

Net cash provided by investing activities

-

-

-

-

-

-20,601

-9,340

-

-

-

-

Cash Flows from Financing Activities:
Proceeds from private placement

10,072

-

-

-

-

-

-

-

-

-

-

Proceeds from common stock financings, net

5,298

-

53,763

49,014

80,599

37,137

40,202

-

-

14,089

-

Sale of Series D redeemable convertible preferred stock and warrants, net of issuance costs

-

-

-

-

-

-

-

-

9,073

-

-

Proceeds from exercise of common stock warrants and options and employee stock purchases

-

-

-

-

-

-

-

4

51

-

-

Dividends paid

-

-

-

-

-

-

-

583

-

-

-

Proceeds from employee stock purchases

121

243

253

-

-

-

-

-

-

132

297

Sale of Series E convertible preferred stock and warrants, net of issuance costs

-

-

-

-

-

-

-

6,023

-

-

-

Proceeds from issuance of note payable

-

-

-

-

-

825

-

-

-

-

-

Proceeds from employee stock purchases

-

-

-

172

-

-

-

-

-

-

-

Proceeds from exercise of common stock options and warrants

3

10,166

5,444

-

-

-

-

-

-

-

-

Proceeds from exercise of common stock options and warrants

-

-

-

2,000

2,546

8,456

-

-

-

-

-

Proceeds from exercise of common stock warrants and options and employee stock purchases

-

-

-

-

-

-

3,527

-

-

-

-

Dividends paid

-

-

-

-

-

798

1,066

-

-

-

-

Payments on note payable

-

209

292

261

120

-

-

-

-

-

-

Payments on capital leases

6

-

-

-

-

-

-

-

-

-

-

Repurchase of common stock

-

-

-

-

-

-

-

-

-

-

41

Payments on capital leases

-

8

11

7

10

5

4

3

8

20

21

Net cash used in financing activities

-

-

-

-

-

45,615

42,659

5,441

-

-

-

Net cash provided by financing activities

15,488

10,192

59,157

50,918

83,015

-

-

-

9,116

14,201

235

Net decrease in cash and cash equivalents

-31,412

-41,509

31,962

54,081

-

-

-

-

-

-

-

Supplemental disclosure of cash flow information:
Cash paid for interest

-

9

42

-

-

-

-

-

-

-

-

Increase to right-of-use asset upon adoption of ASC 842

1,236

-

-

-

-

-

-

-

-

-

-

Increase to lease liability upon adoption of ASC 842

1,236

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash financing and investing activities:
Non-cash property additions

-

-

150

-

-

-

-

-

-

-

-

Accrued financing transaction costs

165

101

17

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

6,615

-6,307

16,182

-14,475

7,563

-8,463

-19,694